title: Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910.
abstract: Squamous cell carcinoma (SCC) of the lung is moderately responsive to anticancer drugs, but no specific chemotherapy regimens have yet been established. We conducted a multicenter phase II study of nedaplatin (NP) and irinotecan (CPT) for SCC of the lung. Fifty patients underwent 4 to 6 cycles of chemotherapy comprising of NP at 100 mg/m(2) on day 1 and CPT at 60 mg/m(2) on days 1 and 8 every 4 weeks. Twenty-seven patients received 4 to 6 cycles of chemotherapy (median=4 cycles). Major toxicities included neutropenia (46.0%), grade 3 or 4 anorexia (22.0%), febrile neutropenia (16.0%), diarrhea (12.0%), hyponatremia (12.0%), grade 4 anemia (10.0%), thrombocytopenia (10.0%) and infection (10.0%). There were no treatment-related deaths. One patient achieved a complete response and 16 a partial response, with an overall response rate of 34.0%. The median survival time was 11.8 months (95% CI=8.3-15.8 months) and the 2-year survival rate was 22.0%. In conclusion, the NP and CPT regimen is not recommend for further evaluation for patients with advanced SCC of the lung.
authors.affiliation: Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: Kouzo
authors.initials: K
authors.lastname: Yamada
authors.affiliation: Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Saito
authors.affiliation: Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kondo
authors.affiliation: Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: Shuji
authors.initials: S
authors.lastname: Murakami
authors.affiliation: Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan.
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Masuda
authors.affiliation: Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan.
authors.forename: Michiko
authors.initials: M
authors.lastname: Yamamoto
authors.affiliation: Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Igawa
authors.affiliation: Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Katono
authors.affiliation: Department of Respiratory Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Takiguchi
authors.affiliation: Department of Respiratory Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Iwasawa
authors.affiliation: Department of Respiratory Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Ryota
authors.initials: R
authors.lastname: Kurimoto
authors.affiliation: Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Okamoto
authors.affiliation: Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Shimokawa
authors.affiliation: Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Hosomi
authors.affiliation: Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Takagi
authors.affiliation: Department of Respiratory Medicine, Toranomon Hospital, Tokyo, Japan.
authors.forename: Kazuma
authors.initials: K
authors.lastname: Kishi
authors.affiliation: Department of Biostatistics and Epidemiology, Yokohama City University of Medicine, Yokohama, Japan.
authors.forename: Mari
authors.initials: M
authors.lastname: Ohba
authors.affiliation: Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan Department of Internal Medicine, Kanagawa Prefectual Ashigarakami Hospital, Matsuda-machi, Japan foshita@ashigarakami-hospital.jp.
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Oshita
authors.affiliation: Thoracic Oncology Research Group, Kanagawa, Japan.
authors.forename: Koshiro
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077146:Irinotecan; C053989:nedaplatin; D002166:Camptothecin
keywords: irinotecan; lung cancer; nedaplatin; squamous cell carcinoma